A digital approach to the care of patients with heart failure, developed by Boehringer Ingelheim and ORCHA, will be rolled out in the northwest of the UK by a primary care
In another example of the pharma industry embracing generative artificial intelligence (GenAI), Boehringer Ingelheim will use technology developed by IBM to rev up antibod
Germany’s Boehringer Ingelheim has made a move to expand its cancer pipeline via a takeover of T3 Pharma, a spinout from the University of Basel in Switzerland.
Combination regimens based on SGLT2 inhibitors and two drugs with different mechanisms of action have shown activity in patients with chronic kidney disease (CKD), raising
After disappointing results in other indications, AnaptysBio has a route to market with its IL-36 receptor inhibitor imsidolimab in a rare and life-threatening form of the